As filed with the Securities and Exchange Commission on December 23, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
________________
BIOCEPT, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 80-0943522 |
(State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) |
9955 Mesa Rim Road
San Diego, CA 92121
(Address of Principal Executive Offices)
________________
Biocept, Inc. Amended and Restated 2013 Equity Incentive Plan
(Full Title of the Plan)
Michael W. Nall
Chief Executive Officer and President
Biocept, Inc.
9955 Mesa Rim Road
San Diego, CA 92121
(Name and Address of Agent for Service)
(858) 320-8200
(Telephone Number, Including Area Code, of Agent for Service)
________________
Copy to:
Charles J. Bair
Asa M. Henin
Cooley llp
4401 Eastgate Mall
San Diego, CA 92121
(858) 550-6000
________________
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ | Accelerated filer ☐ |
Non-accelerated filer ☑ | Smaller reporting company ☑ |
| Emerging Growth Company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
| | | | |
| | Proposed | | |
Title of Each Class | | Maximum | Proposed Maximum | |
of Securities to | Amount to be | Offering | Aggregate | Amount of |
be Registered | Registered (1) | Price per Share | Offering Price | Registration Fee |
Common Stock (par value $0.0001 per share) | 681,131 shares (2) | $4.53 (3) | $3,085,524 (3) | $337 |
Common Stock (par value $0.0001 per share) | 798,869 shares(4) | $4.93 (5) | $3,938,425 (5) | $430 |
Total | 1,480,000 shares | | | $767 |
(1) | Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of the Registrant’s common stock that may become issuable under the Biocept, Inc. Amended and Restated 2013 Equity Incentive Plan (the “2013 Plan”) by reason of any stock dividend, stock split, recapitalization or other similar transaction. |
(2) | Represents shares reserved for issuance upon the exercise of outstanding stock options, which options were granted from the 730,000 increase in shares authorized under the 2013 Plan, as adjusted for the 1:10 reverse stock split of the Registrant’s common stock on September 4, 2020, which increase was approved by the Registrant’s stockholders on June 5, 2020. |
(3) | This estimate is made pursuant to Rule 457(h)(1) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price are based upon the weighted-average exercise price for the Registrant’s common stock subject to these outstanding stock options. |
(4) | Represents (i) additional shares of the Registrant’s common stock available for future issuance under the 2013 Plan pursuant to a 730,000 increase in the number of shares authorized under the 2013 Plan, as adjusted for the 1:10 reverse stock split of the Registrant’s common stock on September 4, 2020, which increase was approved by the Registrant’s stockholders on June 5, 2020, less the shares subject to outstanding options described in note 2 above, and (ii) 750,000 shares of the Registrant’s common stock added to the 2013 Plan, which shares are reserved for issuance exclusively for the grant of stock awards to employees of the Registrant who have not previously been one of the Registrant’s employees or directors, except following a bona fide period of non-employment, as an inducement material to the individual’s entering into employment with the Registrant within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. |
(5) | This estimate is made pursuant to Rule 457(c) and Rule 457(h)(1) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price are based upon the average of the high and low prices of the Registrant’s common stock on December 21, 2020, as reported on the Nasdaq Capital Market. |
INCORPORATION BY REFERENCE OF CONTENTS OF
REGISTRATION STATEMENTS ON FORM S-8
This registration statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a registration statement of the Registrant on Form S-8 relating to the same benefit plan is effective. The Registrant previously registered shares of its common stock for issuance under the 2013 Plan under Registration Statements on Form S-8 filed with the Securities and Exchange Commission on March 31, 2014 (No. 333-194930), March 11, 2015 (No. 333-202656), August 13, 2015 (No. 333-206347), August 5, 2016 (No. 333-212960), May 15, 2017 (No. 333-218018), September 10, 2018 (No. 333-227267), October 19, 2018 (No. 333-227900) and August 15, 2019 (No. 333-233285). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of those Registration Statements.
Item 8. Exhibits
| | | | |
| | | | |
Exhibits: | Description | | |
3.1 | Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.1.4 of the Registrant’s Current Report on Form 8-K, filed with the SEC on February 14, 2014). | |
3.2 | Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2.1 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013). | |
3.3 | Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on September 29, 2016). | |
3.4 | Amendment to Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on September 29, 2017). | |
3.5 | Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on July 6, 2018). | |
3.6 | Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on September 4, 2020). | |
3.7 | Certificate of Designation of Preference, Rights and Limitations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on August 13, 2018). | |
4.1 | Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4, 3.5, 3.6 and 3.7. | |
4.2 | Specimen Common Stock certificate of Biocept, Inc. (incorporated by reference to Exhibit 4.2 of the Registrant’s Quarterly Report on Form 10-Q, filed with the SEC on November 16, 2020). | |
5.1 | Opinion of Cooley LLP. | |
23.1 | Consent of Mayer Hoffman McCann P.C., an Independent Registered Public Accounting Firm. | |
23.2 | Consent of Cooley LLP. Reference is made to Exhibit 5.1. | |
24.1 | Power of Attorney. Reference is made to the signature page hereto. | |
99.1 | Biocept, Inc. Amended and Restated 2013 Equity Incentive Plan, Form of Stock Option Grant Notice, Option Agreement, Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit agreement for use thereunder. | |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on December 23, 2020.
| | |
BIOCEPT, INC. |
| |
By: | | /s/ Michael W. Nall |
| | Michael W. Nall |
| | President and Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael W. Nall and Timothy Kennedy, and each of them, as his true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him and in his name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
| | |
| | |
Signature | Title | Date |
| | |
/s/ Michael W. Nall Michael W. Nall | Chief Executive Officer, President and Director (Principal Executive Officer) | December 23, 2020 |
| | |
/s/ Timothy Kennedy Timothy Kennedy | Chief Financial Officer, Senior Vice-President of Operations and Secretary (Principal Financial Officer and Principal Accounting Officer) | December 23, 2020 |
| | |
/s/ M. Faye Wilson M. Faye Wilson | Interim Chair and Director | December 23, 2020 |
| | |
/s/ David F. Hale David F. Hale | Director | December 23, 2020 |
| | |
/s/ Marsha A. Chandler Marsha A. Chandler | Director | December 23, 2020 |
| | |
/s/ Bruce E. Gerhardt Bruce E. Gerhardt | Director | December 23, 2020 |
| | |
/s/ Ivor Royston Ivor Royston | Director | December 23, 2020 |
| | |
/s/ Samuel D. Riccitelli Samuel D. Riccitelli | Director | December 23, 2020 |
